(Reuters Health)—Patients who receive biologic infusions at home may have a higher risk of adverse events than those who receive the infusions at a health care facility, a new study suggests.1
Researchers examined administrative claims data on 57,220 adults who received a total of 752,150 biologic infusions for immune-mediated disease between 2007 and 2017. The analysis included a total of 34,078 (4.5%) home infusions for 3,954 patients, as well as 718,072 (95.5%) facility infusions for 54,770 patients.
Compared with facility infusions, home infusions were associated with a significantly higher risk of an emergency department visit or hospital admission on the day of infusion or the following day (odds ratio [OR] 1.25).
Home infusions were also associated with a significantly greater chance that patients would discontinue treatment after an emergency department visit or hospital admission (OR 1.28).
“In an infusion center or office setting, biologic infusions are overseen by trained physicians with experience and resources for managing side effects and complications, which is typically not the case when biologic infusions are administered at home,” says lead study author Matthew Baker, MD, clinical chief for the Division of Immunology and Rheumatology in the Department of Medicine at Stanford University, California.
When issues arise in the home setting, there may be a lower threshold for escalation of care, Dr. Baker says by email.
“Thus, it is not surprising that we found an increased risk of emergency department visit or hospital admission within 24 hours of home infusions compared with facility infusions,” Dr. Baker says.
There were some key differences between patients who had home infusions. For example, they were younger (mean age: 43.2) years than patients who got facility infusions (mean age: 51.3 years). And they were also more likely to be male (41%) than patients who got facility infusions (31.4%).
The proportion of home infusions resulting in emergency department visits and hospital admissions was highest after the first biologic infusion at home (4.9%), then dropped with the second infusion (4.3%) and third infusion (3.9%) of the same medicine.
Researchers didn’t find any difference in post-infusion mortality between home- and facility-administered infusions.
One limitation of the claims data analysis is that there may be a potential for residual or unmeasured confounders to influence the outcomes, the study team notes in JAMA Network Open. Researchers also lacked data on disease-modifying medications, such as methotrexate, as well as other medications that may have influenced the risk of adverse events with infusions.1
